News & Events

Orchestra BioMed™ Announces AHA 2018 Presentation on BackBeat® Cardiac Neuromodulation Therapy (CNT)

November 8, 2018

  • Novel Treatment Delivers Immediate, Substantial, and Sustained Reduction in Blood Pressure
  • Potential to Become a Broadly Applicable Therapy for Device-Based Hypertension Management

Orchestra BioMed™ Strengthens Operations, R&D and Pharmaceutical Development Expertise with Key Leadership Team Additions

October 10, 2018

  • Ron Dadino appointed Vice President, Pharmaceutical Development & Operations, Cardiovascular Interventions
  • Greg Kopia, Ph.D., CMPP appointed Director, Pre-Clinical Development, Cardiovascular Interventions
  • Ziv Belsky appointed Vice President, Research & Development, Cardiac Neuromodulation

Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board

October 9, 2018

  • Eric A. Rose, M.D., biotech and medical device business leader as well as world-renowned cardiac surgeon and scientist who performed the landmark achievement of the first successful pediatric heart transplant
  • Jason Aryeh, life sciences industry expert, investment fund manager and Director of licensing juggernaut Ligand Pharmaceuticals
  • Gary J. Pruden, former Worldwide Chairman for Johnson & Johnson Medical Devices Group and Executive Vice President of Johnson & Johnson
  • Expanded Strategic Advisory Board offers exceptional industry, product development, commercialization and capital markets strategic insight and expertise

Orchestra BioMed™ Bolsters Leadership Team with Appointment of Inessa Wheeler as Vice President, Strategy and Marketing

October 8, 2018

Ms. Wheeler brings extensive track record in marketing, strategy and commercial program development

New Hope, PA., October 8, 2018 - Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence based therapeutic solutions for medical procedures that address major medical conditions, announced today that it has appointed Inessa Wheeler, MBA, as Vice President of Strategy and Marketing.


Orchestra BioMed™ Announces Presentation of Positive 2-Year Clinical Results and Program Update for BackBeat® Cardiac Neuromodulation Therapy at TCT 2018

September 25, 2018

Immediate, Substantial, and Sustained Reduction in Blood Pressure Demonstrates Potential to Offer Highly Differentiated, Breakthrough Treatment for Hypertension

San Diego, CA., September 25, 2018 - Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, presented positive 2-year clinical results from its multicenter clinical trial for BackBeat® Cardiac Neuromodulation Therapy (CNT) at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San Diego, CA. Daniel Burkhoff, M.D., Ph.D., Director, Heart Failure, Hemodynamics and Mechanical Circulatory Support Research for the Cardiovascular Research Foundation, presented clinical outcomes of the Moderato I Study, which demonstrated immediate, substantial and sustained reduction in blood pressure when BackBeat CNT was used in patients with persistent hypertension (office BP > 150mmHg) despite two or more anti-hypertensive medications and an indication for a pacemaker.


Orchestra BioMed™ Announces Presentation of 3-Year Clinical Results for Virtue® Sirolimus-Eluting Balloon at TCT 2018

September 24, 2018

Excellent Long-Term Safety and Efficacy Profile Demonstrate Potential to Offer Valuable New Treatment for Coronary In-Stent Restenosis

San Diego, CA., September 24, 2018 - Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, announced the 3-year clinical results from its Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San Diego, CA. Juan Granada, M.D., Associate Professor of Medicine at the Columbia University College of Physicians and Surgeons and President and CEO of Cardiovascular Research Foundation, presented the outcomes of SABRE trial, which demonstrated excellent efficacy and safety performance of the Virtue® Sirolimus-Eluting Balloon (SEB) in a very challenging patient population with predominantly long, diffuse restenosis lesions within stents that had been implanted an average of nearly 4 years prior to the study enrollment. The primary safety and efficacy per protocol endpoint results of the study were as follows:


Three-Month Data from the Moderato-HTN Trial Published

December 23, 2017

American Heart Association Journal

3-months data from Moderato-HTN first-in-human clinical study was published in the American Heart Association Journal. The study was an open-label, single-arm, multicenter, prospective trial investigating the safety and efficacy of BackBeat PHC pacing therapy in patients with persistent hypertension indicated for implantation or replacement of a dual-chamber pacemaker.


Abstract on BackBeat® CNT Awarded Best Abstract at the International Conference for Innovations

December 5, 2017

International Conference for Innovation (ICI), Tel Aviv, Israel

BackBeat’s abstract entitled “Two-Year Experience with Programmable Hypertension Control Therapy: A Novel Treatment for Hypertension” was awarded best abstract at the International Conference for Innovation (ICI) that took place in Tel Aviv, Israel on December 3-5, 2017 and helped create a lot of buzz throughout the conference about this transformational therapy.


Angiographic Results and 1-Year Clinical Outcomes from the SABRE Trial Published

October 23, 2017

JACC: Cardiovascular Interventions

Angiographic results and 1-year clinical outcomes of the SABRE (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis) trial were published in JACC: Cardiovascular Interventions, October 2017.


BackBeat Medical Wins Top Honor in TCT 2016 Shark Tank Innovation Competition

November 4, 2016

Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC.

NEW HOPE, Pa., Nov. 4, 2016 /PRNewswire/ -- BackBeat Medical Inc. today announced that the company's patented Programmable Hypertension Control (PHC) therapy received first place in the Shark Tank Innovation Competition at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 conference in Washington, DC.


Results of Multicenter Clinical Study Demonstrate BackBeat's Patented Technology Creates a Potential Breakthrough in Device-Based Treatment of Hypertension

August 28, 2016

The Journal of Innovation in Cardiac Rhythm Management

BackBeat Medical Inc. today announced the presentation of data demonstrating a significant and sustained reduction in blood pressure in patients with hypertension using the company's patented cardiac pacing-based treatment.


Have any questions?
Contact us at 917.254.4900 or info@orchestrabiomed.com